Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan 6517619651, Iran.
Department of Genomics and Genetic Engineering, Razi Vaccine and Serum Research Institute (RVSRI), Karaj 3197619751, Iran.
Nanoscale Res Lett. 2014 Jul 9;9(1):340. doi: 10.1186/1556-276X-9-340. eCollection 2014.
This paper describes the production, purification, and immobilization of l-asparaginase II (ASNase II) in chitosan nanoparticles (CSNPs). ASNase II is an effective antineoplastic agent, used in the acute lymphoblastic leukemia chemotherapy. Cloned ASNase II gene (ansB) in pAED4 plasmid was transformed into Escherichia coli BL21pLysS (DE3) competent cells and expressed under optimal conditions. The lyophilized enzyme was loaded into CSNPs by ionotropic gelation method. In order to get optimal entrapment efficiency, CSNP preparation, chitosan/tripolyphosphate (CS/TPP) ratio, and protein loading were investigated. ASNase II loading into CSNPs was confirmed by Fourier transform infrared (FTIR) spectroscopy, and morphological observation was carried out by transmission electron microscopy. Three absolute CS/TPP ratios were studied. Entrapment efficiency and loading capacity increased with increasing CS and TPP concentration. The best ratio was applied for obtaining optimal ASNase II-loaded CSNPs with the highest entrapment efficiency. Size, zeta potential, entrapment efficiency, and loading capacity of the optimal ASNase II-CSNPs were 340 ± 12 nm, 21.2 ± 3 mV, 76.2% and 47.6%, respectively. The immobilized enzyme showed an increased in vitro half-life in comparison with the free enzyme. The pH and thermostability of the immobilized enzyme was comparable with the free enzyme. This study leads to a better understanding of how to prepare CSNPs, how to achieve high encapsulation efficiency for a high molecular weight protein, and how to prolong the release of protein from CSNPs. A conceptual understanding of biological responses to ASNase II-loaded CSNPs is needed for the development of novel methods of drug delivery.
本文描述了壳聚糖纳米粒子(CSNPs)中 l-天冬酰胺酶 II(ASNase II)的生产、纯化和固定化。ASNase II 是一种有效的抗肿瘤药物,用于急性淋巴细胞白血病的化疗。克隆的 ASNase II 基因(ansB)在 pAED4 质粒中被转化到大肠杆菌 BL21pLysS(DE3)感受态细胞中,并在最佳条件下表达。冻干酶通过离子凝胶化方法载入 CSNPs 中。为了获得最佳的包封效率,研究了 CSNP 制备、壳聚糖/三聚磷酸钠(CS/TPP)的比例和蛋白质负载量。通过傅里叶变换红外(FTIR)光谱证实了 ASNase II 载入 CSNPs,并用透射电子显微镜进行了形态观察。研究了三个绝对 CS/TPP 比例。包封效率和载药量随 CS 和 TPP 浓度的增加而增加。最佳比例用于获得具有最高包封效率的最佳 ASNase II 载入 CSNPs。最佳 ASNase II-CSNPs 的粒径、Zeta 电位、包封效率和载药量分别为 340±12nm、21.2±3mV、76.2%和 47.6%。与游离酶相比,固定化酶的体外半衰期增加。固定化酶的 pH 和热稳定性与游离酶相当。这项研究有助于更好地理解如何制备 CSNPs,如何为高分子量蛋白质实现高包封效率,以及如何延长蛋白质从 CSNPs 中的释放。需要对 ASNase II 载入 CSNPs 的生物反应有一个概念性的理解,以便开发新的药物输送方法。